nodes	percent_of_prediction	percent_of_DWPC	metapath
Ingenol Mebutate—Application site scab—Imiquimod—skin cancer	0.0704	0.128	CcSEcCtD
Ingenol Mebutate—Application site swelling—Imiquimod—skin cancer	0.0704	0.128	CcSEcCtD
Ingenol Mebutate—Application site discharge—Imiquimod—skin cancer	0.0509	0.0922	CcSEcCtD
Ingenol Mebutate—Application site ulcer—Imiquimod—skin cancer	0.0509	0.0922	CcSEcCtD
Ingenol Mebutate—Application site erosion—Imiquimod—skin cancer	0.0405	0.0733	CcSEcCtD
Ingenol Mebutate—Application site exfoliation—Imiquimod—skin cancer	0.0405	0.0733	CcSEcCtD
Ingenol Mebutate—Application site paraesthesia—Imiquimod—skin cancer	0.0338	0.0613	CcSEcCtD
Ingenol Mebutate—Application site warmth—Imiquimod—skin cancer	0.0338	0.0613	CcSEcCtD
Ingenol Mebutate—Application site vesicles—Imiquimod—skin cancer	0.0292	0.053	CcSEcCtD
Ingenol Mebutate—PRKCA—skin epidermis—skin cancer	0.0181	0.104	CbGeAlD
Ingenol Mebutate—PRKCD—nipple—skin cancer	0.0159	0.0911	CbGeAlD
Ingenol Mebutate—PRKCA—nerve—skin cancer	0.0154	0.0885	CbGeAlD
Ingenol Mebutate—PRKCA—endothelium—skin cancer	0.0131	0.0753	CbGeAlD
Ingenol Mebutate—PRKCA—blood vessel—skin cancer	0.0121	0.0695	CbGeAlD
Ingenol Mebutate—Application site burn—Imiquimod—skin cancer	0.0116	0.0211	CcSEcCtD
Ingenol Mebutate—PRKCD—connective tissue—skin cancer	0.0112	0.0646	CbGeAlD
Ingenol Mebutate—Application site erythema—Imiquimod—skin cancer	0.0103	0.0187	CcSEcCtD
Ingenol Mebutate—PRKCD—skin of body—skin cancer	0.0102	0.0583	CbGeAlD
Ingenol Mebutate—Application site pruritus—Imiquimod—skin cancer	0.00998	0.0181	CcSEcCtD
Ingenol Mebutate—PRKCD—mammalian vulva—skin cancer	0.00926	0.0532	CbGeAlD
Ingenol Mebutate—Application site irritation—Imiquimod—skin cancer	0.00878	0.0159	CcSEcCtD
Ingenol Mebutate—PRKCA—neck—skin cancer	0.00865	0.0497	CbGeAlD
Ingenol Mebutate—PRKCD—lymphoid tissue—skin cancer	0.00822	0.0472	CbGeAlD
Ingenol Mebutate—PRKCD—female reproductive system—skin cancer	0.00793	0.0456	CbGeAlD
Ingenol Mebutate—Scab—Imiquimod—skin cancer	0.00766	0.0139	CcSEcCtD
Ingenol Mebutate—Instillation site pain—Imiquimod—skin cancer	0.00748	0.0135	CcSEcCtD
Ingenol Mebutate—PRKCD—head—skin cancer	0.00663	0.0381	CbGeAlD
Ingenol Mebutate—Application site burn—Fluorouracil—skin cancer	0.00642	0.0116	CcSEcCtD
Ingenol Mebutate—PRKCA—connective tissue—skin cancer	0.0062	0.0356	CbGeAlD
Ingenol Mebutate—PRKCA—epithelium—skin cancer	0.00589	0.0338	CbGeAlD
Ingenol Mebutate—PRKCA—skin of body—skin cancer	0.0056	0.0322	CbGeAlD
Ingenol Mebutate—Application site pain—Imiquimod—skin cancer	0.00554	0.01	CcSEcCtD
Ingenol Mebutate—Eyelid oedema—Imiquimod—skin cancer	0.00483	0.00875	CcSEcCtD
Ingenol Mebutate—PRKCD—lymph node—skin cancer	0.00464	0.0267	CbGeAlD
Ingenol Mebutate—PRKCA—lymphoid tissue—skin cancer	0.00453	0.026	CbGeAlD
Ingenol Mebutate—Periorbital oedema—Bleomycin—skin cancer	0.00438	0.00793	CcSEcCtD
Ingenol Mebutate—PRKCA—female reproductive system—skin cancer	0.00437	0.0251	CbGeAlD
Ingenol Mebutate—Scab—Fluorouracil—skin cancer	0.00423	0.00767	CcSEcCtD
Ingenol Mebutate—PRKCA—head—skin cancer	0.00365	0.021	CbGeAlD
Ingenol Mebutate—Application site pain—Fluorouracil—skin cancer	0.00306	0.00554	CcSEcCtD
Ingenol Mebutate—Ulcer—Imiquimod—skin cancer	0.00258	0.00467	CcSEcCtD
Ingenol Mebutate—PRKCA—lymph node—skin cancer	0.00256	0.0147	CbGeAlD
Ingenol Mebutate—Swelling—Imiquimod—skin cancer	0.00201	0.00363	CcSEcCtD
Ingenol Mebutate—Ulcer—Bleomycin—skin cancer	0.00183	0.00332	CcSEcCtD
Ingenol Mebutate—Ulcer—Dactinomycin—skin cancer	0.00171	0.00309	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Vismodegib—skin cancer	0.00162	0.00293	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Vemurafenib—skin cancer	0.0016	0.0029	CcSEcCtD
Ingenol Mebutate—Infestation—Vemurafenib—skin cancer	0.0016	0.0029	CcSEcCtD
Ingenol Mebutate—Ulcer—Fluorouracil—skin cancer	0.00142	0.00258	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Imiquimod—skin cancer	0.00136	0.00247	CcSEcCtD
Ingenol Mebutate—Infestation—Imiquimod—skin cancer	0.00136	0.00247	CcSEcCtD
Ingenol Mebutate—Eye disorder—Vemurafenib—skin cancer	0.00134	0.00243	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Imiquimod—skin cancer	0.00133	0.0024	CcSEcCtD
Ingenol Mebutate—Erythema—Vemurafenib—skin cancer	0.00125	0.00226	CcSEcCtD
Ingenol Mebutate—Eye pain—Temozolomide—skin cancer	0.00117	0.00213	CcSEcCtD
Ingenol Mebutate—Eye disorder—Imiquimod—skin cancer	0.00114	0.00207	CcSEcCtD
Ingenol Mebutate—Swelling—Fluorouracil—skin cancer	0.00111	0.00201	CcSEcCtD
Ingenol Mebutate—Erythema—Imiquimod—skin cancer	0.00107	0.00193	CcSEcCtD
Ingenol Mebutate—Infection—Vemurafenib—skin cancer	0.00101	0.00183	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Vemurafenib—skin cancer	0.001	0.00181	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Fluorouracil—skin cancer	0.000874	0.00158	CcSEcCtD
Ingenol Mebutate—Infection—Imiquimod—skin cancer	0.000864	0.00156	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Imiquimod—skin cancer	0.000853	0.00154	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Temozolomide—skin cancer	0.000817	0.00148	CcSEcCtD
Ingenol Mebutate—Infestation—Temozolomide—skin cancer	0.000817	0.00148	CcSEcCtD
Ingenol Mebutate—Swelling—Docetaxel—skin cancer	0.000799	0.00145	CcSEcCtD
Ingenol Mebutate—Erythema—Bleomycin—skin cancer	0.000757	0.00137	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Fluorouracil—skin cancer	0.000753	0.00136	CcSEcCtD
Ingenol Mebutate—Infestation—Fluorouracil—skin cancer	0.000753	0.00136	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Fluorouracil—skin cancer	0.000732	0.00133	CcSEcCtD
Ingenol Mebutate—Erythema—Dactinomycin—skin cancer	0.000706	0.00128	CcSEcCtD
Ingenol Mebutate—Eye disorder—Temozolomide—skin cancer	0.000685	0.00124	CcSEcCtD
Ingenol Mebutate—Headache—Vemurafenib—skin cancer	0.000639	0.00116	CcSEcCtD
Ingenol Mebutate—Erythema—Temozolomide—skin cancer	0.000639	0.00116	CcSEcCtD
Ingenol Mebutate—Nasopharyngitis—Docetaxel—skin cancer	0.000631	0.00114	CcSEcCtD
Ingenol Mebutate—Infection—Bleomycin—skin cancer	0.000614	0.00111	CcSEcCtD
Ingenol Mebutate—Erythema—Fluorouracil—skin cancer	0.000588	0.00107	CcSEcCtD
Ingenol Mebutate—Infection—Dactinomycin—skin cancer	0.000572	0.00104	CcSEcCtD
Ingenol Mebutate—Headache—Imiquimod—skin cancer	0.000545	0.000987	CcSEcCtD
Ingenol Mebutate—Infestation NOS—Docetaxel—skin cancer	0.000543	0.000984	CcSEcCtD
Ingenol Mebutate—Infestation—Docetaxel—skin cancer	0.000543	0.000984	CcSEcCtD
Ingenol Mebutate—Conjunctivitis—Docetaxel—skin cancer	0.000528	0.000957	CcSEcCtD
Ingenol Mebutate—Infection—Temozolomide—skin cancer	0.000518	0.000938	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Temozolomide—skin cancer	0.000511	0.000926	CcSEcCtD
Ingenol Mebutate—Infection—Fluorouracil—skin cancer	0.000477	0.000864	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Fluorouracil—skin cancer	0.000471	0.000853	CcSEcCtD
Ingenol Mebutate—Eye disorder—Docetaxel—skin cancer	0.000456	0.000826	CcSEcCtD
Ingenol Mebutate—Erythema—Docetaxel—skin cancer	0.000425	0.000769	CcSEcCtD
Ingenol Mebutate—Infection—Docetaxel—skin cancer	0.000344	0.000624	CcSEcCtD
Ingenol Mebutate—Nervous system disorder—Docetaxel—skin cancer	0.00034	0.000616	CcSEcCtD
Ingenol Mebutate—PRKCA—VEGFA-VEGFR2 Pathway—NRAS—skin cancer	0.000327	0.00119	CbGpPWpGaD
Ingenol Mebutate—Headache—Temozolomide—skin cancer	0.000326	0.000591	CcSEcCtD
Ingenol Mebutate—PRKCD—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000325	0.00119	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by EGFR—KRAS—skin cancer	0.000324	0.00118	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Apoptosis—TP53—skin cancer	0.000323	0.00118	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by EGFR in Cancer—KRAS—skin cancer	0.000321	0.00117	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—PTGER4—skin cancer	0.000321	0.00117	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by PDGF—KRAS—skin cancer	0.00032	0.00117	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Downstream signaling of activated FGFR—HRAS—skin cancer	0.000319	0.00117	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Transmission across Chemical Synapses—BRAF—skin cancer	0.000315	0.00115	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle—MLH1—skin cancer	0.000315	0.00115	CbGpPWpGaD
Ingenol Mebutate—PRKCA—G Protein Signaling Pathways—KRAS—skin cancer	0.000314	0.00115	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways in Glioblastoma—TP53—skin cancer	0.000309	0.00113	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—MC1R—skin cancer	0.000308	0.00113	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by VEGF—NRAS—skin cancer	0.000308	0.00113	CbGpPWpGaD
Ingenol Mebutate—PRKCA—NGF signalling via TRKA from the plasma membrane—BRAF—skin cancer	0.000308	0.00112	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Downstream signaling of activated FGFR—IL6—skin cancer	0.000305	0.00112	CbGpPWpGaD
Ingenol Mebutate—PRKCD—MAPK Signaling Pathway—TP53—skin cancer	0.000303	0.00111	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—GLI2—skin cancer	0.000302	0.0011	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Insulin Signaling—HRAS—skin cancer	0.000301	0.0011	CbGpPWpGaD
Ingenol Mebutate—Headache—Fluorouracil—skin cancer	0.000301	0.000545	CcSEcCtD
Ingenol Mebutate—PRKCD—Downstream signal transduction—HRAS—skin cancer	0.0003	0.0011	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by FGFR—HRAS—skin cancer	0.000298	0.00109	CbGpPWpGaD
Ingenol Mebutate—PRKCD—EGF/EGFR Signaling Pathway—HRAS—skin cancer	0.000298	0.00109	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by ERBB2—HRAS—skin cancer	0.000297	0.00108	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Myometrial Relaxation and Contraction Pathways—IL6—skin cancer	0.000296	0.00108	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways in Glioblastoma—HRAS—skin cancer	0.000296	0.00108	CbGpPWpGaD
Ingenol Mebutate—PRKCD—DAP12 signaling—HRAS—skin cancer	0.000296	0.00108	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—SHH—skin cancer	0.000293	0.00107	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—ENO2—skin cancer	0.000293	0.00107	CbGpPWpGaD
Ingenol Mebutate—PRKCD—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	0.00029	0.00106	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—TLR7—skin cancer	0.000288	0.00105	CbGpPWpGaD
Ingenol Mebutate—PRKCA—PDGFR-beta signaling pathway—NRAS—skin cancer	0.000288	0.00105	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—MC1R—skin cancer	0.000288	0.00105	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Downstream signal transduction—IL6—skin cancer	0.000287	0.00105	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by FGFR—IL6—skin cancer	0.000286	0.00104	CbGpPWpGaD
Ingenol Mebutate—PRKCA—ErbB1 downstream signaling—KRAS—skin cancer	0.000285	0.00104	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by ERBB2—IL6—skin cancer	0.000284	0.00104	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—GLI1—skin cancer	0.000284	0.00104	CbGpPWpGaD
Ingenol Mebutate—PRKCD—DAP12 signaling—IL6—skin cancer	0.000283	0.00103	CbGpPWpGaD
Ingenol Mebutate—PRKCA—VEGFA-VEGFR2 Pathway—KRAS—skin cancer	0.000281	0.00103	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—MC1R—skin cancer	0.00028	0.00102	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.00028	0.00102	CbGpPWpGaD
Ingenol Mebutate—PRKCD—DAP12 interactions—HRAS—skin cancer	0.000278	0.00102	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by FGFR in disease—HRAS—skin cancer	0.000278	0.00102	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by EGFR—HRAS—skin cancer	0.000276	0.00101	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by Wnt—TERT—skin cancer	0.000275	0.001	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by EGFR in Cancer—HRAS—skin cancer	0.000273	0.000997	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by PDGF—HRAS—skin cancer	0.000272	0.000993	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—SUFU—skin cancer	0.000269	0.000983	CbGpPWpGaD
Ingenol Mebutate—PRKCA—G Protein Signaling Pathways—HRAS—skin cancer	0.000267	0.000976	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by FGFR in disease—IL6—skin cancer	0.000266	0.000972	CbGpPWpGaD
Ingenol Mebutate—PRKCD—DAP12 interactions—IL6—skin cancer	0.000266	0.000972	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by VEGF—KRAS—skin cancer	0.000265	0.000969	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	0.000264	0.000964	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by EGFR—IL6—skin cancer	0.000264	0.000963	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Cytokine Signaling in Immune system—NRAS—skin cancer	0.000263	0.000962	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by SCF-KIT—NRAS—skin cancer	0.000262	0.000956	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by EGFR in Cancer—IL6—skin cancer	0.000261	0.000955	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by PDGF—IL6—skin cancer	0.00026	0.00095	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Wnt Signaling Pathway and Pluripotency—TP53—skin cancer	0.00026	0.000948	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by NGF—NRAS—skin cancer	0.000259	0.000945	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—FOXO4—skin cancer	0.000259	0.000945	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—PLIN2—skin cancer	0.000257	0.000939	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—FOXO4—skin cancer	0.000255	0.000932	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Downstream signaling of activated FGFR—NRAS—skin cancer	0.000251	0.000915	CbGpPWpGaD
Ingenol Mebutate—PRKCA—PDGFR-beta signaling pathway—KRAS—skin cancer	0.000248	0.000906	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—CSPG4—skin cancer	0.000248	0.000904	CbGpPWpGaD
Ingenol Mebutate—PRKCD—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	0.000246	0.000899	CbGpPWpGaD
Ingenol Mebutate—PRKCA—ErbB1 downstream signaling—HRAS—skin cancer	0.000243	0.000886	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Neuronal System—BRAF—skin cancer	0.000241	0.000881	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—FOXO4—skin cancer	0.000239	0.000872	CbGpPWpGaD
Ingenol Mebutate—PRKCA—VEGFA-VEGFR2 Pathway—HRAS—skin cancer	0.000239	0.000872	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.000238	0.000869	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by NGF—BRAF—skin cancer	0.000237	0.000864	CbGpPWpGaD
Ingenol Mebutate—PRKCD—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	0.000236	0.000861	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Downstream signal transduction—NRAS—skin cancer	0.000235	0.00086	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by FGFR—NRAS—skin cancer	0.000234	0.000856	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by ERBB2—NRAS—skin cancer	0.000233	0.000851	CbGpPWpGaD
Ingenol Mebutate—PRKCA—DAP12 signaling—NRAS—skin cancer	0.000232	0.000847	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Spinal Cord Injury—TP53—skin cancer	0.000231	0.000843	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PTCH2—skin cancer	0.000229	0.000835	CbGpPWpGaD
Ingenol Mebutate—PRKCA—VEGFA-VEGFR2 Pathway—IL6—skin cancer	0.000229	0.000835	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.000228	0.000832	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Cytokine Signaling in Immune system—KRAS—skin cancer	0.000227	0.000828	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by VEGF—HRAS—skin cancer	0.000226	0.000823	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by SCF-KIT—KRAS—skin cancer	0.000225	0.000823	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by NGF—KRAS—skin cancer	0.000223	0.000814	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by FGFR in disease—NRAS—skin cancer	0.000218	0.000797	CbGpPWpGaD
Ingenol Mebutate—PRKCA—DAP12 interactions—NRAS—skin cancer	0.000218	0.000797	CbGpPWpGaD
Ingenol Mebutate—Headache—Docetaxel—skin cancer	0.000217	0.000393	CcSEcCtD
Ingenol Mebutate—PRKCA—Signaling by EGFR—NRAS—skin cancer	0.000216	0.00079	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by VEGF—IL6—skin cancer	0.000216	0.000788	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Downstream signaling of activated FGFR—KRAS—skin cancer	0.000216	0.000787	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by EGFR in Cancer—NRAS—skin cancer	0.000214	0.000783	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by PDGF—NRAS—skin cancer	0.000213	0.00078	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Spinal Cord Injury—IL6—skin cancer	0.000211	0.000772	CbGpPWpGaD
Ingenol Mebutate—PRKCA—PDGFR-beta signaling pathway—HRAS—skin cancer	0.000211	0.00077	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—CSPG4—skin cancer	0.000207	0.000757	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—SHH—skin cancer	0.000205	0.000749	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—RASA1—skin cancer	0.000204	0.000745	CbGpPWpGaD
Ingenol Mebutate—PRKCA—GPCR downstream signaling—PTGER4—skin cancer	0.000203	0.00074	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Downstream signal transduction—KRAS—skin cancer	0.000203	0.00074	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by FGFR—KRAS—skin cancer	0.000202	0.000736	CbGpPWpGaD
Ingenol Mebutate—PRKCA—EGF/EGFR Signaling Pathway—KRAS—skin cancer	0.000202	0.000736	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by ERBB2—KRAS—skin cancer	0.000201	0.000733	CbGpPWpGaD
Ingenol Mebutate—PRKCA—DAP12 signaling—KRAS—skin cancer	0.0002	0.000729	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—SHH—skin cancer	0.0002	0.000729	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—PTCH1—skin cancer	0.000195	0.00071	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—SMO—skin cancer	0.000195	0.00071	CbGpPWpGaD
Ingenol Mebutate—PRKCA—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	0.000193	0.000706	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Cytokine Signaling in Immune system—HRAS—skin cancer	0.000193	0.000704	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	0.000193	0.000704	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by SCF-KIT—HRAS—skin cancer	0.000192	0.0007	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by NGF—HRAS—skin cancer	0.000189	0.000692	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—PTGER4—skin cancer	0.000189	0.000692	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—PTCH1—skin cancer	0.000189	0.000691	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—SMO—skin cancer	0.000189	0.000691	CbGpPWpGaD
Ingenol Mebutate—PRKCA—DAP12 interactions—KRAS—skin cancer	0.000188	0.000686	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by FGFR in disease—KRAS—skin cancer	0.000188	0.000686	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000187	0.000682	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by EGFR—KRAS—skin cancer	0.000186	0.00068	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by EGFR in Cancer—KRAS—skin cancer	0.000185	0.000674	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Cytokine Signaling in Immune system—IL6—skin cancer	0.000184	0.000673	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—PTGER4—skin cancer	0.000184	0.000672	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by PDGF—KRAS—skin cancer	0.000184	0.000671	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by SCF-KIT—IL6—skin cancer	0.000183	0.00067	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Gene Expression—ERCC2—skin cancer	0.000183	0.000669	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Downstream signaling of activated FGFR—HRAS—skin cancer	0.000183	0.000669	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by NGF—IL6—skin cancer	0.000181	0.000662	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle, Mitotic—CDK4—skin cancer	0.000179	0.000653	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle—TERT—skin cancer	0.000179	0.000652	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	0.000177	0.000646	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Downstream signaling of activated FGFR—IL6—skin cancer	0.000175	0.000641	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—GLI2—skin cancer	0.000173	0.000633	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Insulin Signaling—HRAS—skin cancer	0.000173	0.000632	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Downstream signal transduction—HRAS—skin cancer	0.000172	0.000629	CbGpPWpGaD
Ingenol Mebutate—PRKCA—EGF/EGFR Signaling Pathway—HRAS—skin cancer	0.000171	0.000626	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by FGFR—HRAS—skin cancer	0.000171	0.000626	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by ERBB2—HRAS—skin cancer	0.000171	0.000623	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—ERCC2—skin cancer	0.00017	0.000622	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Myometrial Relaxation and Contraction Pathways—IL6—skin cancer	0.00017	0.000621	CbGpPWpGaD
Ingenol Mebutate—PRKCA—DAP12 signaling—HRAS—skin cancer	0.00017	0.00062	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—ENO2—skin cancer	0.000168	0.000615	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—SHH—skin cancer	0.000168	0.000615	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—FOXO4—skin cancer	0.000167	0.000611	CbGpPWpGaD
Ingenol Mebutate—PRKCA—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	0.000166	0.000608	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—MC1R—skin cancer	0.000165	0.000604	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Downstream signal transduction—IL6—skin cancer	0.000165	0.000602	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by FGFR—IL6—skin cancer	0.000164	0.000599	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Hemostasis—NRAS—skin cancer	0.000164	0.000599	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by ERBB2—IL6—skin cancer	0.000163	0.000596	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—GLI1—skin cancer	0.000163	0.000595	CbGpPWpGaD
Ingenol Mebutate—PRKCA—DAP12 signaling—IL6—skin cancer	0.000162	0.000593	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000161	0.000587	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle—CDK4—skin cancer	0.00016	0.000584	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by FGFR in disease—HRAS—skin cancer	0.00016	0.000583	CbGpPWpGaD
Ingenol Mebutate—PRKCA—DAP12 interactions—HRAS—skin cancer	0.00016	0.000583	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—TERT—skin cancer	0.00016	0.000583	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by EGFR—HRAS—skin cancer	0.000158	0.000578	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	0.000157	0.000574	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by EGFR in Cancer—HRAS—skin cancer	0.000157	0.000573	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by PDGF—HRAS—skin cancer	0.000156	0.00057	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—SUFU—skin cancer	0.000155	0.000564	CbGpPWpGaD
Ingenol Mebutate—PRKCA—DAP12 interactions—IL6—skin cancer	0.000153	0.000558	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by FGFR in disease—IL6—skin cancer	0.000153	0.000558	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by EGFR—IL6—skin cancer	0.000151	0.000553	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by EGFR in Cancer—IL6—skin cancer	0.00015	0.000548	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by PDGF—IL6—skin cancer	0.000149	0.000546	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by NGF—NRAS—skin cancer	0.000149	0.000543	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—FOXO4—skin cancer	0.000149	0.000543	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Innate Immune System—NRAS—skin cancer	0.000148	0.000539	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Transmission across Chemical Synapses—HRAS—skin cancer	0.000145	0.000529	CbGpPWpGaD
Ingenol Mebutate—PRKCA—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	0.000141	0.000517	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Hemostasis—KRAS—skin cancer	0.000141	0.000516	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—ENO2—skin cancer	0.000141	0.000515	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—FOXO4—skin cancer	0.000137	0.000501	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.000137	0.000499	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle, Mitotic—CDKN2A—skin cancer	0.000137	0.000499	CbGpPWpGaD
Ingenol Mebutate—PRKCA—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	0.000135	0.000494	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.000131	0.000478	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by NGF—KRAS—skin cancer	0.000128	0.000467	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Innate Immune System—KRAS—skin cancer	0.000127	0.000464	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—BRAF—skin cancer	0.000126	0.000461	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Hemostasis—TP53—skin cancer	0.000125	0.000458	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle—CDKN2A—skin cancer	0.000122	0.000446	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Hemostasis—HRAS—skin cancer	0.00012	0.000438	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—SHH—skin cancer	0.000118	0.00043	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—RASA1—skin cancer	0.000117	0.000428	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—TERT—skin cancer	0.000112	0.000408	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PTCH1—skin cancer	0.000112	0.000408	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—SMO—skin cancer	0.000112	0.000408	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Neuronal System—HRAS—skin cancer	0.000111	0.000405	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by NGF—HRAS—skin cancer	0.000109	0.000397	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—PTGER4—skin cancer	0.000109	0.000397	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Innate Immune System—HRAS—skin cancer	0.000108	0.000395	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Gene Expression—ERCC2—skin cancer	0.000105	0.000385	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by NGF—IL6—skin cancer	0.000104	0.00038	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Innate Immune System—IL6—skin cancer	0.000103	0.000378	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—PTGS2—skin cancer	0.000102	0.000373	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—ERCC2—skin cancer	9.78e-05	0.000357	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—FOXO4—skin cancer	9.61e-05	0.000351	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—NRAS—skin cancer	9.42e-05	0.000344	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—NRAS—skin cancer	9.41e-05	0.000344	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—TERT—skin cancer	9.16e-05	0.000335	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—BRAF—skin cancer	8.85e-05	0.000323	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—NRAS—skin cancer	8.6e-05	0.000314	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—NRAS—skin cancer	8.48e-05	0.00031	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—ERCC2—skin cancer	8.19e-05	0.000299	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—KRAS—skin cancer	8.11e-05	0.000296	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—KRAS—skin cancer	8.1e-05	0.000296	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—NRAS—skin cancer	7.94e-05	0.00029	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—KRAS—skin cancer	7.4e-05	0.00027	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—KRAS—skin cancer	7.3e-05	0.000267	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—BRAF—skin cancer	7.26e-05	0.000265	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—TP53—skin cancer	7.21e-05	0.000263	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Hemostasis—HRAS—skin cancer	6.89e-05	0.000252	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—HRAS—skin cancer	6.89e-05	0.000251	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—KRAS—skin cancer	6.84e-05	0.00025	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Cell Cycle—TP53—skin cancer	6.8e-05	0.000248	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling by GPCR—IL6—skin cancer	6.59e-05	0.000241	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—TERT—skin cancer	6.42e-05	0.000234	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—HRAS—skin cancer	6.29e-05	0.00023	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—HRAS—skin cancer	6.21e-05	0.000227	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Immune System—IL6—skin cancer	6.02e-05	0.00022	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Innate Immune System—IL6—skin cancer	5.94e-05	0.000217	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—PTGS2—skin cancer	5.86e-05	0.000214	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—HRAS—skin cancer	5.81e-05	0.000212	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—NRAS—skin cancer	5.56e-05	0.000203	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Disease—IL6—skin cancer	5.56e-05	0.000203	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—NRAS—skin cancer	5.41e-05	0.000197	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—BRAF—skin cancer	5.08e-05	0.000186	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—NRAS—skin cancer	4.94e-05	0.00018	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Metabolism—PTGS2—skin cancer	4.91e-05	0.000179	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—KRAS—skin cancer	4.79e-05	0.000175	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—KRAS—skin cancer	4.65e-05	0.00017	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—NRAS—skin cancer	4.56e-05	0.000167	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—TP53—skin cancer	4.25e-05	0.000155	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—KRAS—skin cancer	4.25e-05	0.000155	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—HRAS—skin cancer	4.07e-05	0.000149	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—HRAS—skin cancer	3.96e-05	0.000144	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—KRAS—skin cancer	3.93e-05	0.000143	CbGpPWpGaD
Ingenol Mebutate—PRKCD—Signaling Pathways—IL6—skin cancer	3.89e-05	0.000142	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling by GPCR—IL6—skin cancer	3.79e-05	0.000138	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—HRAS—skin cancer	3.61e-05	0.000132	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Immune System—IL6—skin cancer	3.46e-05	0.000126	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—HRAS—skin cancer	3.34e-05	0.000122	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—NRAS—skin cancer	3.19e-05	0.000117	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Disease—IL6—skin cancer	3.19e-05	0.000117	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—KRAS—skin cancer	2.75e-05	0.0001	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—TP53—skin cancer	2.44e-05	8.92e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—HRAS—skin cancer	2.34e-05	8.53e-05	CbGpPWpGaD
Ingenol Mebutate—PRKCA—Signaling Pathways—IL6—skin cancer	2.24e-05	8.17e-05	CbGpPWpGaD
